Published in Cell Death Differ on November 11, 2011
Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther (2013) 1.27
Tumor suppressor WWOX binds to ΔNp63α and sensitizes cancer cells to chemotherapy. Cell Death Dis (2013) 1.02
Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. Oncotarget (2012) 1.00
Influenza A viruses control expression of proviral human p53 isoforms p53β and Delta133p53α. J Virol (2012) 0.98
Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death Differ (2014) 0.97
p73 regulates autophagy and hepatocellular lipid metabolism through a transcriptional activation of the ATG5 gene. Cell Death Differ (2013) 0.97
The p53 isoforms are differentially modified by Mdm2. Cell Cycle (2012) 0.94
Caspase-1 is a novel target of p63 in tumor suppression. Cell Death Dis (2013) 0.93
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities. Oncotarget (2014) 0.86
Rapamycin regulates biochemical metabolites. Cell Cycle (2013) 0.84
p63 threonine phosphorylation signals the interaction with the WW domain of the E3 ligase Itch. Cell Cycle (2014) 0.84
Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. Oncotarget (2012) 0.82
Molecular dynamics of the full-length p53 monomer. Cell Cycle (2013) 0.82
Impact of G-quadruplex structures and intronic polymorphisms rs17878362 and rs1642785 on basal and ionizing radiation-induced expression of alternative p53 transcripts. Carcinogenesis (2014) 0.80
The p53 isoform Δ133p53β promotes cancer stem cell potential. Stem Cell Reports (2015) 0.80
Role of p53 isoforms and aggregations in cancer. Medicine (Baltimore) (2016) 0.79
p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure-Function Continuum Concept. Int J Mol Sci (2016) 0.78
TAp63γ demethylation regulates protein stability and cellular distribution during neural stem cell differentiation. PLoS One (2012) 0.78
Damage-inducible intragenic demethylation of the human TP53 tumor suppressor gene is associated with transcription from an alternative intronic promoter. Mol Carcinog (2015) 0.77
Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness. Int J Mol Sci (2016) 0.75
MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics (2005) 11.75
p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell (1998) 11.54
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell (1997) 7.27
p53 isoforms can regulate p53 transcriptional activity. Genes Dev (2005) 6.76
Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell (1999) 4.87
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ (2006) 3.49
Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol (1987) 3.22
p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev (2009) 2.57
DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med (2002) 2.48
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev (2005) 2.44
Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ (2001) 2.40
p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ (2011) 1.94
Human embryonic stem-cell derivatives for full reconstruction of the pluristratified epidermis: a preclinical study. Lancet (2009) 1.91
Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol (2002) 1.89
The p53 family and programmed cell death. Oncogene (2008) 1.81
Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol Cell Biol (2002) 1.72
The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63. J Biol Chem (2005) 1.49
Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem (2002) 1.37
p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage. Cell Death Differ (2010) 1.36
p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene (2002) 1.36
p63 and p73 transactivate differentiation gene promoters in human keratinocytes. Biochem Biophys Res Commun (2000) 1.28
In vitro culture conditions to study keratinocyte differentiation using the HaCaT cell line. Cytotechnology (2007) 1.28
DeltaNp63 is essential for epidermal commitment of embryonic stem cells. PLoS One (2008) 1.27
Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1. Proc Natl Acad Sci U S A (1988) 1.27
p53 regulates the transcription of its Delta133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. Oncogene (2010) 1.26
Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript. FEBS Lett (2010) 1.17
Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes. Oncogene (2003) 1.15
ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes. Oncogene (2007) 1.13
A pure population of ectodermal cells derived from human embryonic stem cells. Stem Cells (2007) 1.13
Mechanisms of transcriptional repression of cell-cycle G2/M promoters by p63. Nucleic Acids Res (2006) 1.13
Differential altered stability and transcriptional activity of ΔNp63 mutants in distinct ectodermal dysplasias. J Cell Sci (2011) 1.11
Transcriptional programs regulated by p63 in normal epithelium and tumors. Cell Cycle (2007) 1.08
Simple sequence repeat polymorphism within the p53 gene. Oncogene (1993) 1.08
DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene (2002) 1.04
A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation of myeloid leukemia cells. Genomics (1996) 0.99
p53 isoforms - a conspiracy to kidnap p53 tumor suppressor activity? Cell Mol Life Sci (2009) 0.98
TA-p63-gamma regulates expression of DeltaN-p63 in a manner that is sensitive to p53. Oncogene (2006) 0.94
Embryonic stem cells as an ectodermal cellular model of human p63-related dysplasia syndromes. Biochem Biophys Res Commun (2010) 0.93
DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. Hum Mutat (2010) 0.88
T antigen is bound to a host protein in SV40-transformed cells. Nature (1979) 17.78
Cancer. p53, guardian of the genome. Nature (1992) 16.36
Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science (1999) 8.43
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J (1990) 6.34
Regulation of the specific DNA binding function of p53. Cell (1992) 6.16
Negative regulation of viral enhancers in undifferentiated embryonic stem cells. Cell (1985) 5.88
p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A (1990) 5.43
An immunoaffinity purification procedure for SV40 large T antigen. Virology (1985) 4.81
Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell (1993) 4.62
SUMO-1 modification activates the transcriptional response of p53. EMBO J (1999) 4.19
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene (1990) 3.89
Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest (2000) 3.78
Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol (1986) 3.72
p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ (2006) 3.49
SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000. Nature (1980) 3.44
Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci (1990) 3.35
p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature (1987) 3.34
The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res (1994) 3.28
An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods (1992) 3.23
High levels of p53 protein in UV-irradiated normal human skin. Oncogene (1993) 3.15
Using the polymerase chain reaction to modify expression plasmids for epitope mapping. Nucleic Acids Res (1989) 3.15
Epigenetic change in IGF2R is associated with fetal overgrowth after sheep embryo culture. Nat Genet (2001) 3.05
Two pathways for base excision repair in mammalian cells. J Biol Chem (1996) 3.01
The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J Clin Invest (1999) 2.98
Small peptides activate the latent sequence-specific DNA binding function of p53. Cell (1995) 2.96
Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A (1997) 2.90
miR-203 represses 'stemness' by repressing DeltaNp63. Cell Death Differ (2008) 2.86
Requirement for the replication protein SSB in human DNA excision repair. Nature (1991) 2.80
Nuclear protein with sequence homology to translation initiation factor eIF-4A. Nature (1988) 2.77
Use of monoclonal antibodies as probes of simian virus 40 T antigen ATPase activity. J Biol Chem (1981) 2.77
Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature (1991) 2.75
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 2.72
A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol (1991) 2.71
A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol (1995) 2.57
An immunochemical investigation of SV40 T antigens. 1. Production properties and specificity of rabbit antibody to purified simian virus 40 large-T antigen. Virology (1978) 2.49
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene (1991) 2.42
p53 in tumour pathology: can we trust immunohistochemistry?--Revisited! J Pathol (1994) 2.41
Structure and function of SV40 large-T antigen. Philos Trans R Soc Lond B Biol Sci (1987) 2.37
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36
The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology (1991) 2.32
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene (1997) 2.31
Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci U S A (1998) 2.28
Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep (2001) 2.27
Allosteric activation of latent p53 tetramers. Curr Biol (1994) 2.25
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol (1997) 2.25
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene (2001) 2.14
DbpA: a DEAD box protein specifically activated by 23s rRNA. EMBO J (1993) 2.04
Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature (1991) 1.99
Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene (1999) 1.98
Nuclear protein p68 is an RNA-dependent ATPase. EMBO J (1989) 1.98
p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet (1991) 1.95
Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene (1994) 1.94
A role for the human single-stranded DNA binding protein HSSB/RPA in an early stage of nucleotide excision repair. Nucleic Acids Res (1992) 1.91
Integrin beta 4 mutations associated with junctional epidermolysis bullosa with pyloric atresia. Nat Genet (1995) 1.90
P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer (2005) 1.83
Characterization of human p53 antigens employing primate specific monoclonal antibodies. Virology (1983) 1.78
Origins of the prestalk-prespore pattern in Dictyostelium development. Cell (1989) 1.78
Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays (1995) 1.75
Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol (1995) 1.75
DNA rearrangement of a homeobox gene in myeloid leukaemic cells. EMBO J (1988) 1.75
An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res (1999) 1.74
Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ (2011) 1.74
Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res (2001) 1.73
In vitro dissection of the membrane and RNP binding activities of influenza virus M1 protein. Virology (2001) 1.70
Cancer. A death in the life of p53. Nature (1993) 1.70
The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays (1993) 1.70
p68 RNA helicase: identification of a nucleolar form and cloning of related genes containing a conserved intron in yeasts. Mol Cell Biol (1991) 1.69
Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer (1990) 1.69
Isolation and analysis of the fission yeast gene encoding polymerase delta accessory protein PCNA. EMBO J (1992) 1.68
Molecular characterization of the hdm2-p53 interaction. J Mol Biol (1997) 1.64
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene (2012) 1.62
Rapid and efficient homing of human CD34(+)CD38(-/low)CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice. Blood (2001) 1.62
Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol (1992) 1.62
Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci (1995) 1.57
Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet (1992) 1.53
Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci U S A (2000) 1.52
Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene (1995) 1.51
Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res (1993) 1.49
Ku selectively transfers between DNA molecules with homologous ends. J Biol Chem (1997) 1.46
Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol (1991) 1.46
The p53 response to ionising radiation in adult and developing murine tissues. Oncogene (1996) 1.46
APC expression in normal human tissues. J Pathol (1997) 1.44
The complex between simian virus 40 T antigen and a specific host protein. Proc R Soc Lond B Biol Sci (1980) 1.41
Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene (1991) 1.40
ΔNp63 is an ectodermal gatekeeper of epidermal morphogenesis. Cell Death Differ (2010) 1.39
The effect of a surgery-specific cardiac output-guided haemodynamic algorithm on outcomes in patients undergoing pancreaticoduodenectomy in a high-volume centre: a retrospective comparative study. Anaesth Intensive Care (2017) 1.39
Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell (1992) 1.39
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer (1991) 1.39
Identification of novel mdm2 binding peptides by phage display. Oncogene (1996) 1.37
Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene (2008) 1.37
The p53 tumour suppressor gene. Br J Surg (1998) 1.37
p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage. Cell Death Differ (2010) 1.36
Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene (1991) 1.36
Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ (2010) 1.35
C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances. Oncogene (2012) 1.35